Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree

Objective: To investigate the clinical phenotype and genetic characteristics of patients with Fabry disease caused by a GLA variant, IVS4+919G>A. Methods: It was a prospective study. Fabry disease screening was conducted among high-risk population in Ninghai from October 2021 to August 2023. Thos...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 62(2024), 4 vom: 25. März, Seite 345-350
1. Verfasser: Ge, Z H (VerfasserIn)
Weitere Verfasser: Lu, Z H, Pan, X D, Lai, T T, Yang, M J, Yang, H Q, Zhang, H B, Li, G Y, Dai, Z Q, Mao, J H
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article alpha-Galactosidase EC 3.2.1.22
LEADER 01000caa a22002652 4500
001 NLM37017058X
003 DE-627
005 20240328000405.0
007 cr uuu---uuuuu
008 240327s2024 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20231007-00258  |2 doi 
028 5 2 |a pubmed24n1351.xml 
035 |a (DE-627)NLM37017058X 
035 |a (NLM)38527505 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Ge, Z H  |e verfasserin  |4 aut 
245 1 0 |a Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 27.03.2024 
500 |a Date Revised 27.03.2024 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To investigate the clinical phenotype and genetic characteristics of patients with Fabry disease caused by a GLA variant, IVS4+919G>A. Methods: It was a prospective study. Fabry disease screening was conducted among high-risk population in Ninghai from October 2021 to August 2023. Those children with decreased α-galactosidase enzyme activity<2.40 μmol/(L·h) or elavated Lyso-GL-3 level>1.10 μg/L in dried blood spot (DBS) method underwent GLA genetic testing for diagnosis confirmation. Meanwhile, family screening was carried out. A proband and his family members diagnosed with Fabry disease were research subjects. The clinical and genetic characteristics of patients with Fabry disease caused by the GLA variant (IVS4+919G>A) were analyzed. Results: The female proband aged 9.8 years with pain in both lower limbs as the initial symptom was found to have a heterozygous GLA variant IVS4+919G>A among 102 patients. In family screening, there were 4 family members (proband's father, elder sister, elder male cousin and elder female cousin) with Fabry disease and a family member (proband's fifth aunt) with a GLA variant. Among these 4 diagnosed family members, the elder male cousin of the proband, a boy aged 13.2 years had a heterozygous GLA variant, IVS4+919G>A with intermittent pain in both lower limbs as the initial symptom. The proband's father had knee joint pain. The proband's elder sister had decreased vision and his elder female cousin had no obvious symptoms. The proband's fifth aunt with a GLA variant had decreased vision. Conclusions: High-risk screening in children and family screening are helpful for early diagnosis and treatment of Fabry disease. Neuropathic pain may be a early symptom in children with Fabry disease caused by the GLA variant, IVS4+919G>A 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a alpha-Galactosidase  |2 NLM 
650 7 |a EC 3.2.1.22  |2 NLM 
700 1 |a Lu, Z H  |e verfasserin  |4 aut 
700 1 |a Pan, X D  |e verfasserin  |4 aut 
700 1 |a Lai, T T  |e verfasserin  |4 aut 
700 1 |a Yang, M J  |e verfasserin  |4 aut 
700 1 |a Yang, H Q  |e verfasserin  |4 aut 
700 1 |a Zhang, H B  |e verfasserin  |4 aut 
700 1 |a Li, G Y  |e verfasserin  |4 aut 
700 1 |a Dai, Z Q  |e verfasserin  |4 aut 
700 1 |a Mao, J H  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 62(2024), 4 vom: 25. März, Seite 345-350  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:62  |g year:2024  |g number:4  |g day:25  |g month:03  |g pages:345-350 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20231007-00258  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 62  |j 2024  |e 4  |b 25  |c 03  |h 345-350